Actively Recruiting
Focal HDR Brachytherapy Boost to Stereotactic Radiotherapy
Led by Centre hospitalier de l'Université de Montréal (CHUM) · Updated on 2025-03-13
150
Participants Needed
2
Research Sites
313 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To determine if fBT+sRT is superior to standard care in terms of urinary toxicity by having fewer patients experience a minimal important decline (MID) in urinary irritation/obstructive QoL
CONDITIONS
Official Title
Focal HDR Brachytherapy Boost to Stereotactic Radiotherapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histological diagnosis of prostate cancer planned for curative-intent HDR brachytherapy boost to external beam radiotherapy to the prostate gland.
- ECOG performance status 0-1
- Charlson Comorbidity Index C= 4
- Imaging visible disease encompassing less than 50% of the prostate gland and consistent with biopsy findings.
You will not qualify if you...
- None
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Centre Hospitalier de l'Université de Montréal
Montreal, Quebec, Canada
Actively Recruiting
2
CHUQ
Québec, Quebec, Canada
Actively Recruiting
Research Team
M
Mom Phat
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here